COMBINATION OF INTRAVENOUS KETAMINE AND ELECTROCONVULSOTHERAPY FOR TREATMENT-RESISTANT DEPRESSION: A SYSTEMATIC REVIEW
Luísa Soares Capa, Gabrielle Simon Tronco, Virginia Nascimento Reinert, J. Klockner, P. M. Mariussi, M. Fighera
International Journal of Health Sciences April 5, 2023 DOI: 10.22533/at.ed.1593252303041 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Interventions | Intravenous ketamine electroconvulsive therapy (ECT) |
| Topics | Depression Esketamine Ketamine |
| Key findings | The authors report that recent studies indicate combining intravenous ketamine with ECT can be an effective treatment for treatment-resistant depression, and they propose it as a promising option for patients who do not respond to other treatments, while cautioning that more research is needed to confirm efficacy and safety. |
Abstract
: Treatment-resistant depression is a common psychiatric disorder that can lead to significant disability and decreased quality of life for patients. In recent years, there has been growing interest in the combination of intravenous ketamine and electroconvulsive therapy (ECT) for the treatment of treatment-resistant depression. Ketamine is an anesthetic that is an N-methyl-D-aspartate (NMDA) receptor antagonist that also has antidepressant properties and has been used to treat treatment-resistant depression. ECT is a treatment for depression that involves applying electric current to the brain to induce therapeutic seizures. Recent studies have shown that the combination of intravenous ketamine and ECT can be an effective treatment for treatment-resistant depression. Although more research is still needed to fully understand the efficacy and safety of the combination of intravenous ketamine and ECT for the treatment of treatment-resistant depression, combination therapy may be a promising option for patients who do not respond to other treatments.
Comparable studies
Other narrative reviews on ketamine for depression, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation Adults with treatment-resistant depression | 2021 | Review | |
| Ketamine: a paradigm shift for depression research and treatment | 2019 | Review | |
| Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective | 2019 | Review | |
| Ketamine: A tale of two enantiomers | 2020 | Review | |
| Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor | 2021 | Review |